ArticleClinical pharmacology and therapeutics2026
Initiation of Gabapentin with Opioids and Risk of Respiratory Cardiovascular and Opioid-Related Adverse Events Following Surgery for Breast Cancer.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pain is a key determinant of quality-of-life following breast cancer surgery, the most common cancer operation in the United States. Gabapentinoids are frequently prescribed for pain management, yet their respiratory, cardiovascular, and opioid-related adverse effects remain unclear. This target trial emulation, analyzing US commercial claims (2013-2023), evaluated these safety outcomes under gabapentin-opioids initiation vs. opioids only during the first postoperative month following breast cancer surgery, with sustained 1-year follow-up. Women with nonmetastatic breast cancer were eligible on surgery dates if they had no prior outcomes, nor gabapentinoids or opioid prescriptions. Outcomes included time-to-first respiratory complications, major adverse cardiovascular events (MACE), arrhythmia, and high-dose opioid utilization (≥ 50 or ≥ 90 morphine -milligram equivalent [MME]). We estimated 1-year outcome risks and 95% CIs under gabapentin-opioids and opioids-only strategies using weighted pooled logistic regressions with bootstrapping, including stabilized inverse probability weighting to adjust for baseline and time-varying confounders. Of 86,290 eligible individuals, 1709 initiated gabapentin and opioids, and 39,372 initiated opioids only. Risks of respiratory complications (RR 1.24, 95% CI: 0.26-3.02), MACE (RR 0.95, 95% CI: 0.31-1.85), and arrhythmia (RR 0.65, 95% CI: 0.24-1.33) were comparable under gabapentin-opioids and opioids-only. Risk of receiving opioid dosage ≥ 50 MME (RR 1.23, 95% CI: 0.85-1.72) and ≥ 90 MME (RR 1.09, 95% CI: 0.43-2.23) were comparable. This study challenged the limited evidence regarding safety concerns of adding gabapentin for pain management, finding that gabapentin-opioids initiation carried comparable respiratory and cardiovascular risks to opioids only following breast cancer surgery. However, we did not find evidence that adjunctive gabapentin reduces subsequent high-dose opioid utilization.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.